Global Superdisintegrants Market Size study, by Type (Natural, Synthetics, Others), Formulation (Tablets, Capsules), Therapeutic Area (Neurological Diseases, Gastrointestinal Diseases, Oncology, Inflammatory Diseases, Infectious Diseases, Cardiovascular Diseases, Hematological Diseases) and Regional Forecasts 2019-2026
Global superdisintegrants market is valued at approximately USD 349.60 million in 2018 and is anticipated to grow with a healthy growth rate of more than 8.10% over the forecast period 2019-2026. Superdisintegrants are combination of substances added to drug formulation that accelerates the disintegration of capsule content or tablets into smaller particles which easily gets dissolved. Increasing adoption of oral disintegrating tablets is one of the major driving factors of global superdisintegrants market. In addition, shifting focus of pharmaceutical manufacturers towards emerging markets is an added advantage for the growth of market. However, less expenditure in R&D activities restricts the market to grow with the expected rate. For instance, the fragmentation of the EU pharmaceutical market resulted in lucrative parallel trade. Neither social security nor patients are benefitted with this and leads to deprival of additional resources for funding R&D.
The regional analysis of global Superdisintegrants market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to rising adoption of synthetic superdisintegrants. Europe also contributes a satisfactory growth in the global Superdisintegrants market due to rising population affected by neurological diseases. Asia-Pacific is also anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing preference to ODTs in developing countries such as India China and Japan.
The leading market player included in this report are:
BASF SE
DowDuPont Inc.
Roquette Freres
DFE Pharma
JRS Pharma
Asahi Kasei Corporation
Merck KGaA
Corel Pharma Chem
Avantor Performance Materials, LLC
Ashland Global Holdings Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Natural
Synthetic
Others
By Formulation:
Tablets
Capsules
By Therapeutic Area:
Neurological Diseases
Gastrointestinal Diseases
Oncology
Inflammatory Diseases
Infectious Diseases
Cardiovascular Diseases
Hematological Diseases
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Global Superdisintegrants Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
The regional analysis of global Superdisintegrants market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to rising adoption of synthetic superdisintegrants. Europe also contributes a satisfactory growth in the global Superdisintegrants market due to rising population affected by neurological diseases. Asia-Pacific is also anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2026 due to increasing preference to ODTs in developing countries such as India China and Japan.
The leading market player included in this report are:
BASF SE
DowDuPont Inc.
Roquette Freres
DFE Pharma
JRS Pharma
Asahi Kasei Corporation
Merck KGaA
Corel Pharma Chem
Avantor Performance Materials, LLC
Ashland Global Holdings Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Natural
Synthetic
Others
By Formulation:
Tablets
Capsules
By Therapeutic Area:
Neurological Diseases
Gastrointestinal Diseases
Oncology
Inflammatory Diseases
Infectious Diseases
Cardiovascular Diseases
Hematological Diseases
By Regions:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Global Superdisintegrants Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
CHAPTER 1. EXECUTIVE SUMMARY
1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1. Superdisintegrants Market, by Type, 2016-2026 (USD Billion)
1.3.2. Superdisintegrants Market, by Formulation, 2016-2026 (USD Billion)
1.3.3. Superdisintegrants Market, by Therapeutic Area, 2016-2026 (USD Billion)
1.3.4. Superdisintegrants Market, by Region, 2016-2026 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. SUPERDISINTEGRANTS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. SUPERDISINTEGRANTS MARKET DYNAMICS
3.1. See Saw Analysis
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. SUPERDISINTEGRANTS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
4.2.1. Political Scenario
4.2.2. Economic Scenario
4.2.3. Social Scenario
4.2.4. Technological Scenario
4.3. Key Buying Criteria (On Demand)
4.4. Regulatory Framework (On Demand)
4.5. Investment Vs Adoption Scenario (On Demand)
4.6. Analyst Recommendation & Conclusion
CHAPTER 5. SUPERDISINTEGRANTS MARKET, BY TYPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Superdisintegrants Market, Sub Segment Analysis
5.4.1. Natural Superdisintegrants
5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.2. Synthetic Superdisintegrants
5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.3. Other Superdisintegrants
5.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 6. SUPERDISINTEGRANTS MARKET, BY FORMULATION
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Superdisintegrants Market, Sub Segment Analysis
6.4.1. Capsules
6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.4.2. Tablets
6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 7. SUPERDISINTEGRANTS MARKET, BY THERAPEUTIC AREA
7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Key Market Players
7.4. Superdisintegrants Market, Sub Segment Analysis
7.4.1. Gastrointestinal Diseases
7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.2. Neurological Diseases
7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.3. Inflammatory Diseases
7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.4. Oncology
7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.5. Cardiovascular Diseases
7.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.6. Infectious Diseases
7.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.7. Hematological Diseases
7.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 8. SUPERDISINTEGRANTS MARKET, BY REGIONAL ANALYSIS
8.1. Superdisintegrants Market, Regional Market Snapshot (2016-2026)
8.2. North America Superdisintegrants Market Snapshot
8.2.1. U.S.
8.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.2. Canada
8.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3. Europe Superdisintegrants Market Snapshot
8.3.1. U.K.
8.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2. Germany
8.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3. Rest of Europe
8.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4. Asia Superdisintegrants Market Snapshot
8.4.1. China
8.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2. India
8.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3. Japan
8.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4. Rest of Asia Pacific
8.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5. Latin America Superdisintegrants Market Snapshot
8.5.1. Brazil
8.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2. Mexico
8.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6. Rest of The World
8.6.1. South America
8.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.2. Middle East and Africa
8.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.6.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Company Market Share (Subject to Data Availability)
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Ashland Global Holdings Inc.
9.3.1.1. Overview
9.3.1.2. Financial (Subject to Data Availability)
9.3.1.3. Product Summary
9.3.1.4. Recent Developments
9.3.2. BASF SE
9.3.3. DowDuPont Inc.
9.3.4. Roquette Freres
9.3.5. DFE Pharma
9.3.6. JRS Pharma
9.3.7. Asahi Kasei Corporation
9.3.8. Merck KGaA
9.3.9. Corel Pharma Chem
9.3.10. Avantor Performance Materials, LLC
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.1.6. Research Assumption
1.1. Market Snapshot
1.2. Key Trends
1.3. Global & Segmental Market Estimates & Forecasts, 2016-2026 (USD Billion)
1.3.1. Superdisintegrants Market, by Type, 2016-2026 (USD Billion)
1.3.2. Superdisintegrants Market, by Formulation, 2016-2026 (USD Billion)
1.3.3. Superdisintegrants Market, by Therapeutic Area, 2016-2026 (USD Billion)
1.3.4. Superdisintegrants Market, by Region, 2016-2026 (USD Billion)
1.4. Estimation Methodology
1.5. Research Assumption
CHAPTER 2. SUPERDISINTEGRANTS MARKET DEFINITION AND SCOPE
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Industry Evolution
2.2.2. Scope of the Study
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
CHAPTER 3. SUPERDISINTEGRANTS MARKET DYNAMICS
3.1. See Saw Analysis
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
CHAPTER 4. SUPERDISINTEGRANTS MARKET INDUSTRY ANALYSIS
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.2. PEST Analysis
4.2.1. Political Scenario
4.2.2. Economic Scenario
4.2.3. Social Scenario
4.2.4. Technological Scenario
4.3. Key Buying Criteria (On Demand)
4.4. Regulatory Framework (On Demand)
4.5. Investment Vs Adoption Scenario (On Demand)
4.6. Analyst Recommendation & Conclusion
CHAPTER 5. SUPERDISINTEGRANTS MARKET, BY TYPE
5.1. Market Snapshot
5.2. Market Performance - Potential Model
5.3. Key Market Players
5.4. Superdisintegrants Market, Sub Segment Analysis
5.4.1. Natural Superdisintegrants
5.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.2. Synthetic Superdisintegrants
5.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
5.4.3. Other Superdisintegrants
5.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
5.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 6. SUPERDISINTEGRANTS MARKET, BY FORMULATION
6.1. Market Snapshot
6.2. Market Performance - Potential Model
6.3. Key Market Players
6.4. Superdisintegrants Market, Sub Segment Analysis
6.4.1. Capsules
6.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
6.4.2. Tablets
6.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
6.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 7. SUPERDISINTEGRANTS MARKET, BY THERAPEUTIC AREA
7.1. Market Snapshot
7.2. Market Performance - Potential Model
7.3. Key Market Players
7.4. Superdisintegrants Market, Sub Segment Analysis
7.4.1. Gastrointestinal Diseases
7.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.1.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.2. Neurological Diseases
7.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.2.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.3. Inflammatory Diseases
7.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.3.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.4. Oncology
7.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.4.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.5. Cardiovascular Diseases
7.4.5.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.5.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.6. Infectious Diseases
7.4.6.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.6.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
7.4.7. Hematological Diseases
7.4.7.1. Market estimates & forecasts, 2016-2026 (USD Billion)
7.4.7.2. Regional breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 8. SUPERDISINTEGRANTS MARKET, BY REGIONAL ANALYSIS
8.1. Superdisintegrants Market, Regional Market Snapshot (2016-2026)
8.2. North America Superdisintegrants Market Snapshot
8.2.1. U.S.
8.2.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.2. Canada
8.2.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.2.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3. Europe Superdisintegrants Market Snapshot
8.3.1. U.K.
8.3.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2. Germany
8.3.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3. Rest of Europe
8.3.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.3.3.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4. Asia Superdisintegrants Market Snapshot
8.4.1. China
8.4.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2. India
8.4.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3. Japan
8.4.3.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.3.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4. Rest of Asia Pacific
8.4.4.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.4.4.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5. Latin America Superdisintegrants Market Snapshot
8.5.1. Brazil
8.5.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2. Mexico
8.5.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.5.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6. Rest of The World
8.6.1. South America
8.6.1.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.1.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.2. Middle East and Africa
8.6.2.1. Market estimates & forecasts, 2016-2026 (USD Billion)
8.6.2.2. Type breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.2.3. Formulation breakdown estimates & forecasts, 2016-2026 (USD Billion)
8.6.2.4. Therapeutic Area breakdown estimates & forecasts, 2016-2026 (USD Billion)
CHAPTER 9. COMPETITIVE INTELLIGENCE
9.1. Company Market Share (Subject to Data Availability)
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Ashland Global Holdings Inc.
9.3.1.1. Overview
9.3.1.2. Financial (Subject to Data Availability)
9.3.1.3. Product Summary
9.3.1.4. Recent Developments
9.3.2. BASF SE
9.3.3. DowDuPont Inc.
9.3.4. Roquette Freres
9.3.5. DFE Pharma
9.3.6. JRS Pharma
9.3.7. Asahi Kasei Corporation
9.3.8. Merck KGaA
9.3.9. Corel Pharma Chem
9.3.10. Avantor Performance Materials, LLC
CHAPTER 10. RESEARCH PROCESS
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.1.6. Research Assumption
